It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

UCB has received FDA approval for its drug Bimzelx for the treatment of moderate-to-severe hidradenitis suppurativa, or HS.

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

United Community Banks, Inc. (NASDAQ:UCB – Get Free Report)’s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $33.62 and last traded at $33.49, with a ...

UCB announced the FDA has approved BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. The approval ...

Korea on Friday approved UCB Korea's new drug for the treatment of a chronic muscle-weakening disease called generalized ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.